FierceBiotech FierceBiotech IT FiercePharma FierceMedicalDevices
FierceBiotech Research FierceVaccines FiercePharma Manufacturing FierceDrugDelivery

Related Topics >> brain cancer | glioblastoma | CDX-110

New brain cancer vaccines target tumor cells

Free Newsletter

FierceVaccines is a weekly update on the vaccine industry, with a special focus on the innovations revolutionizing the development and production of vaccines. Join thousands of lab research professionals who get FierceVaccines via weekly email. Sign up today!


CNN takes an in-depth look at the research being done on new therapeutic vaccines for glioblastoma, a lethal brain cancer that has virtually always carried a death sentence with each diagnosis.

One prominent project involves CDX-110, a vaccine that was first developed at Celldex and then partnered with Pfizer, which triggers a T-cell attack on EGFR factor three, a protein produced by 40 percent of tumor cells.

Dr. John Sampson tells CNN that EGFRviii is a kind of genetic fingerprint that plays a crucial role in spurring a targeted immune response.

But a separate program underway at UC San Francisco is even more targeted. University researchers are developing a therapeutic vaccine using the tumor cells taken from each patient. In this case the target is heat-shock protein, also made by tumor cells. And the work is completely funded by the NCI and non-profit groups.

"This is the ultimate personalized medicine," says Dr. Andrew Parsa. "It's like having a lot of little medicines instead of one big blockbuster."

- here's the story from CNN

Related Articles:
Brain cancer vaccine a success in mid-stage trial
Avastin nabs quick glioblastoma OK
Brain cancer vaccine doubles survival time

Email Twitter Facebook LinkedIn StumbleUpon
Get Your FREE FierceVaccines Email Newsletter:
Be the first to comment
More stories about brain cancer   glioblastoma   CDX-110  


Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

This question is for testing whether you are a human visitor and to prevent automated spam submissions.